Entrada Therapeutics (TRDA) Enterprise Value (2022 - 2025)
Historic Enterprise Value for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$93.3 million.
- Entrada Therapeutics' Enterprise Value fell 1952.24% to -$93.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$93.3 million, marking a year-over-year decrease of 1952.24%. This contributed to the annual value of -$101.2 million for FY2024, which is 4971.6% down from last year.
- According to the latest figures from Q3 2025, Entrada Therapeutics' Enterprise Value is -$93.3 million, which was down 1952.24% from -$72.5 million recorded in Q2 2025.
- Entrada Therapeutics' 5-year Enterprise Value high stood at -$45.2 million for Q4 2022, and its period low was -$263.9 million during Q1 2022.
- Moreover, its 4-year median value for Enterprise Value was -$79.7 million (2023), whereas its average is -$124.2 million.
- Its Enterprise Value has fluctuated over the past 5 years, first surged by 7593.29% in 2023, then plummeted by 13231.26% in 2024.
- Over the past 4 years, Entrada Therapeutics' Enterprise Value (Quarter) stood at -$45.2 million in 2022, then tumbled by 49.7% to -$67.6 million in 2023, then crashed by 49.72% to -$101.2 million in 2024, then rose by 7.83% to -$93.3 million in 2025.
- Its Enterprise Value was -$93.3 million in Q3 2025, compared to -$72.5 million in Q2 2025 and -$67.8 million in Q1 2025.